The Adapting Disease Specific Outcome Measures Pilot Trial for Telehealth in Myasthenia Gravis

Inclusion Criteria: * Has the capacity to understand and sign an informed consent form * Diagnosed with acquired autoimmune MG based on clinical syndrome and seropositivity for MG associated autoantibodies (AChR binding, MuSK, or LRP4 antibodies), and/or a decremental response on repetitive nerve stimulation, positive single-fiber electromyography or positive edrophonium test * Subject has been previously evaluated in a face-to-face clinical encounter at one of the participating study sites within the prior 3 years * Primary language is English, or equivalent level of English language fluency * Required disease severity range from asymptomatic-mild to moderate-severe as previously judged by the Investigator. Exclusion Criteria: * Inadequate technology for telehealth visits as assessed by the Investigator (e.g., no internet connection, no laptop/tablet with video capability, etc). Cellular phones are not acceptable. Subjects must use a laptop or tablet. * Is unable or unwilling to comply with the study procedures, including video recording, or telehealth visit. * Any significant medical/psychiatric condition that, in the opinion of the Investigator, may interfere with interpretation of subject evaluation(s) or protocol compliance * Known pregnancy * MGFA severity class IVb or V * Concurrent participation in an interventional clinical trial